HC Wainwright reiterated their buy rating on shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) in a research report sent to investors on Friday, Benzinga reports. HC Wainwright currently has a $32.00 price target on the biotechnology company’s stock. A number of other research analysts have also weighed in on IOVA. The Goldman Sachs Group […]